bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Up 337.2% in April

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 240,900 shares, a growth of 337.2% from the March 31st total of 55,100 shares. Currently, 4.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 221,200 shares, the short-interest ratio is currently 1.1 days.

bioAffinity Technologies Stock Performance

Shares of bioAffinity Technologies stock traded down $0.04 during mid-day trading on Thursday, reaching $2.41. 112,596 shares of the stock traded hands, compared to its average volume of 182,546. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.77 and a quick ratio of 1.76. The business has a 50-day moving average of $2.16 and a 200 day moving average of $1.71. bioAffinity Technologies has a fifty-two week low of $0.95 and a fifty-two week high of $3.62.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings data on Monday, April 1st. The company reported ($0.26) EPS for the quarter. bioAffinity Technologies had a negative net margin of 313.34% and a negative return on equity of 107.20%. The firm had revenue of $2.21 million during the quarter.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.